Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation.

Despite some advances, pancreatic ductal adenocarcinoma (PDAC) remains generally refractory to current treatments. Desmoplastic stroma, a consistent hallmark of PDAC, has emerged as a major source of therapeutic resistance and thus potentially promising targets for improved treatment. The glycan-bin...

Descripción completa

Detalles Bibliográficos
Autores: Martínez-Bosch, Neus, Fernández-Barrena, Maite G, Moreno, Mireia, Ortiz-Zapater, Elena, Munné-Collado, Jessica, Iglesias, Mar, André, Sabine, Gabius, Hans-Joachim, Hwang, Rosa F, Poirier, Françoise, Navas, Carolina, Guerra, Carmen, Fernández-Zapico, Martin E, Navarro, Pilar
Tipo de recurso: artículo
Fecha de publicación:2014
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/23068
Acceso en línea:https://hdl.handle.net/20.500.12105/23068
Access Level:acceso abierto
Palabra clave:Adenocarcinoma
Animals
Carcinoma, Pancreatic Ductal
Cell Line, Tumor
Cell Proliferation
Cell Transformation, Neoplastic
Desmoplastic Small Round Cell Tumor
Galectin 1
HEK293 Cells
Hedgehog Proteins
Humans
Mice
Neovascularization, Pathologic
Pancreatic Neoplasms
RNA Interference
RNA, Small Interfering
Descripción
Sumario:Despite some advances, pancreatic ductal adenocarcinoma (PDAC) remains generally refractory to current treatments. Desmoplastic stroma, a consistent hallmark of PDAC, has emerged as a major source of therapeutic resistance and thus potentially promising targets for improved treatment. The glycan-binding protein galectin-1 (Gal1) is highly expressed in PDAC stroma, but its roles there have not been studied. Here we report functions and molecular pathways of Gal1 that mediate its oncogenic properties in this setting. Genetic ablation of Gal1 in a mouse model of PDAC (EIa-myc mice) dampened tumor progression by inhibiting proliferation, angiogenesis, desmoplasic reaction and by stimulating a tumor-associated immune response, yielding a 20% increase in relative lifesplan. Cellular analyses in vitro and in vivo suggested these effects were mediated through the tumor microenvironment. Importantly, acinar-to-ductal metaplasia, a crucial step for initiation of PDAC, was found to be regulated by Gal1. Mechanistic investigations revealed that Gal1 promoted Hedgehog pathway signaling in PDAC cells and stromal fibroblasts as well as in Ela-myc tumors. Taken together, our findings establish a function for Gal1 in tumor-stroma crosstalk in PDAC and provide a preclinical rationale for Gal1 targeting as a microenvironment-based therapeutic strategy.